Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) on September 29, 2023, regarding events occurring on that date. The report details the appointment of a new independent director to the Company's Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors size increased from eight to nine members.
- New Appointment: Allan Douglas Kirk, MD, PhD, FACS, was appointed as an independent director, effective October 2, 2023.
- Committee Assignment: Dr. Kirk is expected to serve on the Science and Technology Committee.
Compensation and Governance Details
In accordance with the Company's director compensation policy, Dr. Kirk's compensation package includes:
- Cash Retainers: $42,000 annually for Board service and $7,875 annually for Science and Technology Committee service.
- Stock Options: An option to purchase 150,437 shares of Common Stock at the market price on the grant date (October 2, 2023).
- Vesting Schedule: 50% of the shares vest on the first anniversary of the grant date, and the remaining 50% vest on the second anniversary.
- Indemnification: Dr. Kirk entered into the Company's standard indemnification agreement, covering expenses such as legal fees, judgments, and settlements arising from his service.
Investor Verification Checklist
- Verify the independence status of Dr. Kirk under Nasdaq Marketplace rules.
- Confirm the total number of directors on the Board is now nine.
- Review the specific vesting terms of the 150,437 stock options granted.
- Check for any potential conflicts of interest or material interests in transactions as disclosed in Regulation S-K Item 404(a).